TrovaGene (TROV) Receiving Somewhat Favorable Media Coverage, Analysis Shows
Media coverage about TrovaGene (NASDAQ:TROV) has been trending somewhat positive this week, Accern reports. The research group identifies negative and positive news coverage by analyzing more than twenty million news and blog sources in real-time. Accern ranks coverage of companies on a scale of negative one to one, with scores closest to one being the most favorable. TrovaGene earned a media sentiment score of 0.03 on Accern’s scale. Accern also gave headlines about the medical research company an impact score of 46.123147323055 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the stock’s share price in the next several days.
Here are some of the headlines that may have impacted Accern’s rankings:
- U.S. shares higher at close of trade; Dow Jones Industrial Average up 0.58% (uk.investing.com)
- Global Cell-free DNA Testing Market Dynamics Report 2017 – Drivers, Restraints, Opportunities, Trends, and Forecasts to 2023 (markets.businessinsider.com)
- Pre-Open Movers 12/15: (DDR) (ALNY) (HES) Higher; (TROV) (VSTM) (CSX) Lower (more…) (streetinsider.com)
- Mid-Day Market Update: ShiftPixy Gains Following Q4 Results; Verastem Shares Plummet (nasdaq.com)
- Why TrovaGene Inc (TROV) Stock Tanked 40% Today (finance.yahoo.com)
TROV has been the subject of several research reports. Maxim Group set a $4.00 target price on TrovaGene and gave the stock a “buy” rating in a research note on Wednesday, October 18th. lowered TrovaGene from a “buy” rating to a “hold” rating in a research note on Wednesday, November 15th.
TrovaGene (NASDAQ:TROV) last announced its quarterly earnings data on Thursday, November 9th. The medical research company reported ($0.12) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.14) by $0.02. TrovaGene had a negative return on equity of 259.94% and a negative net margin of 7,960.05%. The firm had revenue of $0.12 million during the quarter.
Trovagene, Inc is a clinical-stage, precision medicine oncology therapeutics company. The Company’s lead drug candidate, PCM-075, is a Polo-like Kinase 1 (PLK1) selective adenosine triphosphate (ATP) competitive inhibitor. PCM-075 has shown preclinical antitumor activity as a single agent and in synergy combinations with more than ten different chemotherapeutics and targeted therapies, such as Zytiga (abiraterone acetate), Beleodaq (belinostat), Quizartinib (AC220), a development stage FLT3 inhibitor, and Velcade (bortezomib) in Acute Myeloid Leukemia (AML), metastatic Castration-Resistant Prostate Cancer (mCRPC) and other liquid and solid tumor cancers.
Receive News & Ratings for TrovaGene Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TrovaGene and related companies with MarketBeat.com's FREE daily email newsletter.